StemSynergy Therapeutics®
"Innovative Stem Cell Research. Targeted Cancer Therapeutics."


The four founders of SSTI hold faculty positions in major medical centers nationwide and have considerable expertise in the developmental pathways that regulate cancer stem cells. As a group, the founders have many decades of experience in cancer research, raised tens of millions of dollars in grant support, and have eight patents filed or pending covering both lead-compounds and novel drug targets relevant to cancer stem cells.

Anthony J. Capobianco, Ph.D.


Dr. Anthony Capobianco is a Professor and Director of the Molecular Oncology Program in the Dewitt Daughtry Department of Surgery, at the University of Miami Miller School of Medicine. Dr. Capobianco’s lab was among the first to characterize the role of Notch signaling in cancer. His current research focuses on novel points of therapeutic intervention within the Notch signaling network. Dr. Capobianco received his Ph.D. degree from Boston University and was a postdoctoral fellow at UCSF.

Ethan Lee, M.D.-Ph.D.

Dr. Ethan Lee is a Professor in Cell & Developmental Biology, Cancer Biology, and Pharmacology at Vanderbilt University. His lab focuses on understanding mechanisms of Wnt signaling and the development of novel approaches to target this pathway. His work has lead to the identification of several classes of drugs against the Wnt pathway currently being developed in the pharmaceutical industry. Dr. Lee received his M.D. and Ph.D. degrees from the University of Texas Southwestern Medical Center, followed by postdoctoral training at Harvard Medical School.

David J. Robbins, Ph.D.

Dr. David Robbins is a Professor of Surgery, Biochemistry and Molecular Biology, at the University of Miami Miller School of Medicine. His research is focused on elucidating the roles Sonic hedgehog (Shh) and Wnt developmental signaling pathways play in cancer. Dr. Robbins has served on the editorial boards of the Journal of Biological Chemistry and Current Cancer Therapy Reviews, and is currently a special editor for Cancer Research. He received his Ph.D. degree from UT Southwestern in Pharmacology, and completed postdoctoral training at UCSF.

William A. Weiss M.D.-Ph.D.

Dr. William Weiss is a Professor of Neurology, Pediatrics, and Neurological Surgery, at the University of California, San Francisco CA. He is an expert on developmental therapeutics, focusing on kinase biology, MYC, and in vivo models of cancer. Dr. Weiss co-leads the Pediatric Malignancies Program within UCSF’s Helen Diller Family Comprehensive Cancer Center, is a senior editor at Cancer Research, and is associate editor of Neuro-Oncology and of Molecular and Cellular Biology. Dr. Weiss received his M.D. and Ph.D. degrees from the Stanford University School of Medicine, and performed postdoctoral training at UCSF. He completed his clinical training in pediatrics at Boston Children’s Hospital, and in neurology at UCSF.

Scientific Team

SSTI has a multidisciplinary team of scientists.

Meet the Team


Meet the founders behind StemSynergy Therapeutics, Inc.



SSTI targets cancer stem cell pathways that drive tumor growth.

Scientific Programs